Cash for quitting: study tests if a month without weed boosts HIV health

NCT ID NCT04866004

Completed Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether people with HIV who regularly use cannabis could stop for 28 days and whether that would improve their mood, pain, sleep, and HIV viral load. Twenty-five participants were given financial incentives to stay cannabis-free, with urine tests to confirm. The goal was to see if this approach is feasible and if it reduces inflammation and distress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: contingency management (financial incentives for cannabis abstinence)
What this could lead to: If successful, this could show that stopping cannabis use for a month helps people with HIV feel less distressed and may improve their HIV control.
What could go wrong: This is a very small pilot study with only 25 participants and no comparison group, so results may not apply broadly. It only tests short-term abstinence, not long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS MARIJUANA

Contacts and locations

Locations

Center for Neurobehavioral Research on Addiction

Houston, Texas, 77054, United States
University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.